Check claims that the meeting allowed an ingredient to be used
A committee advising the US drug agency, the Food and Drug Administration (FDA), met on July 23–24, 2026. The committee discussed semax, epitalon, emideltide, MOTS-c, TB-500, KPV and BPC-157. The question was whether to add these seven ingredients to the list allowed for making medicines to order.
Before the meeting, the staff proposed against adding each of those ingredients.
As of September 26, 2026, the checked FDA pages and official records contained neither a written meeting summary nor a word-for-word account nor an official record of the votes. This does not show that no vote took place. The meeting videos were not reviewed for this guide.
The committee gives advice. FDA still has to propose a rule, invite public comments and issue a final rule to change the ingredient list. Ask to see that final rule, not just a meeting announcement.
The list is a separate step
The list covers raw ingredients for making a medicine to order for a named patient. That process is called compounding. The official name is the 503A bulks list. “Bulks” means raw ingredients, before they are made into medicine. “503A” identifies the part of the law for medicines made for individual patients.
A vote by that advisory group would not, by itself, change the legal position.
FDA considers the advice and other reviews before making a final determination.
What this means for a care conversation
Ask the prescriber which current rule permits the exact preparation they are considering. A headline about a meeting cannot answer that on its own.
Someone who asked FDA to add an ingredient can take that request back. Withdrawing that request gives the pharmacy no permission to use the ingredient. It does not change the legal requirements.